Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2016

View Archived Issues

Lycera studies LYC-55716 in phase I/IIa trial in locally advanced or metastatic cancer

Targeting the NK-1 receptor has antispastic effects after chronic spinal injury

PF-06648671 reduces cerebrospinal fluid amyloid-beta after single and multiple doses

ROSGard demonstrates renal protective effect during radiation therapy

Amgen patents appelin receptor agonists

EMA validates Oxervate MAA for neurotrophic keratitis

BioMarin Pharmaceutical begins phase III study of vosoritide in achondroplasia

Flexion Therapeutics submits NDA to FDA for Zilretta

Metabolite profiling shows anandamide is linked to nonalcoholic steatohepatitis in obesity

Purdue Pharma and Exicure enter collaboration agreement in psoriasis

Achaogen reports favorable results from phase III trials of plazomicin

University of Michigan discloses cyclic peptides

Idenix Pharmaceuticals describes prodrugs of gemcitabine

Almirall and Nuevolution to jointly develop RORgammat inhibitors

Pharmascience develops TEC kinase inhibitors

Eiger BioPharmaceuticals reports interim results from phase II study of exendin 9-39 in PBH

First preclinical data for LOXO-195

Novel model reveals roles of Iroquois homeobox proteins in left ventricular noncompaction

M-DGN-549: a new ADC for cancer

Preclinical data on TPC-144 for the treatment of AML and SCLC

Phase II data show efficacy of pembrolizumab for cutaneous T-cell lymphomas

Bayer and Versant Ventures establish BlueRock Therapeutics

Phase IIa results further support potential of RedHill Biopharma's RHB-104 in multiple sclerosis

Defymed collaborates with Semma Therapeutics to develop innovative treatment for type 1 diabetes

Revance reports interim data from phase II study of RT-002 in cervical dystonia

Arimoclomol shows safety and efficacy in phase II trial in patients with ALS due to SOD1 mutation

IGNITE Immunotherapy launches, will focus on oncolytic virus vaccines with lead investor, Pfizer

Astellas Pharma transfers Qutenza to Grunenthal

MeiraGTx expands pipeline with program targeting retromer

EC grants marketing authorization to Arzerra in combination with FC for CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...